carnitine has been researched along with Myocardial Infarction in 78 studies
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Administration of L-carnitine in patients with anterior acute myocardial infarction (AMI) prevents left ventricular remodeling." | 9.12 | Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. ( Boni, L; Bruzzi, P; Iliceto, S; Rizzon, P; Scrutinio, D; Tarantini, G, 2006) |
| "In a randomised, double-blind placebo-controlled trial, the effects of the administration of oral L-carnitine (2 g/day) for 28 days were compared in the management of 51 (carnitine group) and 50 (placebo group) patients with suspected acute myocardial infarction." | 9.08 | A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. ( Agarwal, P; Beegum, R; Niaz, MA; Rastogi, SS; Sachan, DS; Singh, RB, 1996) |
| "L-Carnitine treatment initiated early after acute myocardial infarction and continued for 12 months can attenuate left ventricular dilation during the first year after an acute myocardial infarction, resulting in smaller left ventricular volumes at 3, 6 and 12 months after the emergent event." | 9.08 | Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. ( Biasco, G; Boni, L; Bruzzi, P; D'Ambrosio, G; Di Biase, M; Hugenholtz, PG; Iliceto, S; Rizzon, P; Scrutinio, D, 1995) |
| "L-carnitine (LC) is considered to have good therapeutic potential for myocardial infarction (MI), but its mechanism has not been clarified." | 8.12 | L-Carnitine Alleviates the Myocardial Infarction and Left Ventricular Remodeling through Bax/Bcl-2 Signal Pathway. ( Kou, JJ; Li, HR; Liu, Y; Pang, XB; Shi, JZ; Tian, JH; Xie, XM; Yan, Y; Zheng, XM, 2022) |
| "Among patients with suspected stable angina pectoris, elevated serum even-chained acylcarnitines were associated with increased risk of cardiovascular death and, to a lesser degree with acute myocardial infarction, independent of traditional risk factors." | 7.85 | Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris. ( Berge, RK; Bjørndal, B; Dierkes, J; Karlsson, T; Mellgren, G; Njølstad, PR; Nygård, O; Olsen, T; Pedersen, ER; Strand, E; Svardal, A; Svingen, GF; Tell, GS, 2017) |
| "Animals with heart failure exhibited depressions in ventricular function, positive inotropic response to isoproterenol, beta-AR receptor density and basal AC activity; these changes were also attenuated by PLC treatment." | 7.72 | Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. ( Dhalla, NS; Ferrari, R; Sethi, R; Wang, X, 2004) |
| "These results indicate that metabolic therapy with propionyl L-carnitine may attenuate defects in the SL membrane and thus may improve heart function in congestive heart failure due to myocardial infarction." | 7.70 | Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. ( Dhalla, KS; Dhalla, NS; Ferrari, R; Ganguly, PK; Sethi, R, 1999) |
| "It was previously reported that inhibition of carnitine synthesis by 3-(2,2,2-trimethyl-hydrazinium) propionate (MET-88) restores left ventricular (LV) systolic and diastolic function in rats with myocardial infarction (MI)." | 7.70 | Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. ( Aoyagi, T; Eto, Y; Hayashi, Y; Kirimoto, T; Matsumoto, A; Momomura, S; Omata, M; Sugiura, S; Yokoyama, I; Yonekura, K, 2000) |
| "To determine whether propionyl-L-carnitine (PLC) administration ameliorates ventricular remodeling after myocardial infarction, we performed coronary occlusion in rats and examined the long-term effects of the drug 19-24 wk after surgery." | 7.68 | Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats. ( Anversa, P; Benatti, P; Bianchi, G; Capasso, JM; Di Paola, ED; English, E; Micheletti, R; Schiavone, A, 1993) |
| "Limitation on infarct size, using propionyl-L-carnitine (Sigma-Tau) by itself and with the calcium entry blocker, tiapamil (Hoffmann-LaRoche), was evaluated in two groups of ten dogs each, during chronic (9 days) myocardial infarction." | 7.68 | Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs. ( Kordenat, K; Leasure, JE, 1991) |
| "The effect of administration of carnitine on the severity of myocardial infarction in rats induced by isoproterenol was studied by following histopathological and biochemical parameters." | 7.67 | Effect of administration of carnitine on the severity of myocardial infarction induced by isoproterenol in rats. ( Kurup, PA; Mathew, S; Menon, PV, 1986) |
| "The effects of L-carnitine on ventricular arrhythmias were evaluated in dogs with acute myocardial ischemia and a supplement of excess free fatty acids (FFA)." | 7.66 | Effects of L-carnitine on ventricular arrhythmias in dogs with acute myocardial ischemia and a supplement of excess free fatty acids. ( Kamikawa, T; Suzuki, Y; Yamazaki, N, 1981) |
| "L-carnitine is a physiologically essential metabolic cofactor that has been shown to provide a plethora of benefits when administered after AMI." | 6.50 | L-carnitine for the treatment of acute myocardial infarction. ( Dinicolantonio, JJ; Lavie, CJ; Liberopoulos, E; McCarty, MF; Niazi, AK; O'Keefe, JH, 2014) |
| " The results of the multicenter, randomized, double-blind Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial suggest that the early and long-term administration of L-carnitine attenuates progressive left ventricular dilatation after acute anterior MI." | 6.41 | Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. ( Colonna, P; Iliceto, S, 2000) |
| "Myocardial infarction was associated with a progressive increase in length of the spared myocytes, whereas the changes in myocyte diameter were apparent only at the 1-mo interval." | 5.29 | Myocyte performance during evolution of myocardial infarction in rats: effects of propionyl-L-carnitine. ( Anversa, P; Bianchi, G; Cheng, W; Li, B; Li, P; Micheletti, R; Park, C; Sonnenblick, EH, 1995) |
| "Administration of L-carnitine in patients with anterior acute myocardial infarction (AMI) prevents left ventricular remodeling." | 5.12 | Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. ( Boni, L; Bruzzi, P; Iliceto, S; Rizzon, P; Scrutinio, D; Tarantini, G, 2006) |
| "In a randomised, double-blind placebo-controlled trial, the effects of the administration of oral L-carnitine (2 g/day) for 28 days were compared in the management of 51 (carnitine group) and 50 (placebo group) patients with suspected acute myocardial infarction." | 5.08 | A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. ( Agarwal, P; Beegum, R; Niaz, MA; Rastogi, SS; Sachan, DS; Singh, RB, 1996) |
| "L-Carnitine treatment initiated early after acute myocardial infarction and continued for 12 months can attenuate left ventricular dilation during the first year after an acute myocardial infarction, resulting in smaller left ventricular volumes at 3, 6 and 12 months after the emergent event." | 5.08 | Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. ( Biasco, G; Boni, L; Bruzzi, P; D'Ambrosio, G; Di Biase, M; Hugenholtz, PG; Iliceto, S; Rizzon, P; Scrutinio, D, 1995) |
| "The treatment with L-carnitine in acute myocardial infarction was tested in 146 patients admitted in a coronary care unit." | 5.06 | [L-carnitine for the treatment of acute myocardial infarct]. ( De Pasquale, B; Menotti, A; Righetti, G, 1990) |
| "A systematic review and meta-analysis of 13 controlled trials (N=3629) was conducted to determine the effects of L-carnitine vs placebo or control on mortality, ventricular arrhythmias (VAs), angina, heart failure, and reinfarction." | 4.89 | L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. ( DiNicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; O'Keefe, JH, 2013) |
| "L-carnitine (LC) is considered to have good therapeutic potential for myocardial infarction (MI), but its mechanism has not been clarified." | 4.12 | L-Carnitine Alleviates the Myocardial Infarction and Left Ventricular Remodeling through Bax/Bcl-2 Signal Pathway. ( Kou, JJ; Li, HR; Liu, Y; Pang, XB; Shi, JZ; Tian, JH; Xie, XM; Yan, Y; Zheng, XM, 2022) |
| " We investigated the association of 105 serum metabolites, including acylcarnitines, amino acids, phospholipids and hexose, with risk of myocardial infarction (MI) and ischemic stroke in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam (27,548 adults) and Heidelberg (25,540 adults) cohorts." | 3.88 | Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohorts. ( Adamski, J; Boeing, H; Floegel, A; Illig, T; Johnson, T; Kaaks, R; Kühn, T; Otto, W; Pischon, T; Prehn, C; Rolle-Kampczyk, U; Sookthai, D; von Bergen, M; Weikert, C, 2018) |
| "Among patients with suspected stable angina pectoris, elevated serum even-chained acylcarnitines were associated with increased risk of cardiovascular death and, to a lesser degree with acute myocardial infarction, independent of traditional risk factors." | 3.85 | Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris. ( Berge, RK; Bjørndal, B; Dierkes, J; Karlsson, T; Mellgren, G; Njølstad, PR; Nygård, O; Olsen, T; Pedersen, ER; Strand, E; Svardal, A; Svingen, GF; Tell, GS, 2017) |
| "Animals with heart failure exhibited depressions in ventricular function, positive inotropic response to isoproterenol, beta-AR receptor density and basal AC activity; these changes were also attenuated by PLC treatment." | 3.72 | Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. ( Dhalla, NS; Ferrari, R; Sethi, R; Wang, X, 2004) |
| "These results indicate that metabolic therapy with propionyl L-carnitine may attenuate defects in the SL membrane and thus may improve heart function in congestive heart failure due to myocardial infarction." | 3.70 | Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. ( Dhalla, KS; Dhalla, NS; Ferrari, R; Ganguly, PK; Sethi, R, 1999) |
| "It was previously reported that inhibition of carnitine synthesis by 3-(2,2,2-trimethyl-hydrazinium) propionate (MET-88) restores left ventricular (LV) systolic and diastolic function in rats with myocardial infarction (MI)." | 3.70 | Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. ( Aoyagi, T; Eto, Y; Hayashi, Y; Kirimoto, T; Matsumoto, A; Momomura, S; Omata, M; Sugiura, S; Yokoyama, I; Yonekura, K, 2000) |
| "To determine whether propionyl-L-carnitine (PLC) administration ameliorates ventricular remodeling after myocardial infarction, we performed coronary occlusion in rats and examined the long-term effects of the drug 19-24 wk after surgery." | 3.68 | Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats. ( Anversa, P; Benatti, P; Bianchi, G; Capasso, JM; Di Paola, ED; English, E; Micheletti, R; Schiavone, A, 1993) |
| "Limitation on infarct size, using propionyl-L-carnitine (Sigma-Tau) by itself and with the calcium entry blocker, tiapamil (Hoffmann-LaRoche), was evaluated in two groups of ten dogs each, during chronic (9 days) myocardial infarction." | 3.68 | Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs. ( Kordenat, K; Leasure, JE, 1991) |
| "The experiments with models of myocardial infarction established that carnitine chloride reduced the size of an ischemic zone, prevented oxidative metabolism, lowered ATP and creatine phosphate levels, inhibited lactate and free fatty acid accumulation in the ischemic myocardium." | 3.68 | [Study of anti-ischemic action of carnitine chloride and its effects on the effectiveness of antianginal agents]. ( Danilovich, MI; Dunaev, VV; Favoritov, VN; Kacharava, VG; Kryzhanovskiĭ, SA; Riabinin, VA; Tishkin, VS, 1990) |
| "The effect of administration of carnitine on the severity of myocardial infarction in rats induced by isoproterenol was studied by following histopathological and biochemical parameters." | 3.67 | Effect of administration of carnitine on the severity of myocardial infarction induced by isoproterenol in rats. ( Kurup, PA; Mathew, S; Menon, PV, 1986) |
| "The effects of L-carnitine on ventricular arrhythmias were evaluated in dogs with acute myocardial ischemia and a supplement of excess free fatty acids (FFA)." | 3.66 | Effects of L-carnitine on ventricular arrhythmias in dogs with acute myocardial ischemia and a supplement of excess free fatty acids. ( Kamikawa, T; Suzuki, Y; Yamazaki, N, 1981) |
| "L-carnitine was randomly administered to 81 patients at an oral dose of g 4/die for 12 months, in addition to the pharmacological treatment generally used." | 2.67 | Controlled study on L-carnitine therapeutic efficacy in post-infarction. ( Bigalli, A; Boem, A; Davini, P; Lamanna, F, 1992) |
| "Carnitine was well tolerated and the efficacy demonstrated on the second day following AMI must be interpreted with caution." | 2.67 | [Anti-arrhythmia treatment using L-carnitine in acute myocardial infarct]. ( Burkart, F; Martina, B; Ritz, R; Weiss, P; Zuber, M, 1992) |
| "L-carnitine is a physiologically essential metabolic cofactor that has been shown to provide a plethora of benefits when administered after AMI." | 2.50 | L-carnitine for the treatment of acute myocardial infarction. ( Dinicolantonio, JJ; Lavie, CJ; Liberopoulos, E; McCarty, MF; Niazi, AK; O'Keefe, JH, 2014) |
| " The results of the multicenter, randomized, double-blind Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial suggest that the early and long-term administration of L-carnitine attenuates progressive left ventricular dilatation after acute anterior MI." | 2.41 | Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. ( Colonna, P; Iliceto, S, 2000) |
| "Preliminary results in patients with cardiac failure suggest that this drug may reduce cardiac arrhythmias and may allow the reduction of digoxin therapy." | 2.38 | New thoughts of pathophysiology and therapy of ischemic heart disease. ( Pepine, CJ, 1991) |
| "l-Carnitine is a cofactor in the energy metabolism pathways where it drives the uptake and oxidation of long chain fatty acids (LCFA) by mitochondria." | 1.40 | Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size. ( Cirule, H; Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Lola, D; Loza, E; Makarova, E; Makrecka, M; Pugovics, O; Sevostjanovs, E; Stonans, I; Vilskersts, R, 2014) |
| "4%) experienced an adverse event." | 1.38 | Metabolic profiles predict adverse events after coronary artery bypass grafting. ( Craig, DM; Granger, CB; Hauser, ER; Haynes, C; Hughes, GC; Kraus, WE; Muehlbauer, MJ; Newby, LK; Newgard, CB; Sebek, JK; Shah, AA; Shah, SH; Stevens, RC, 2012) |
| " In conclusion, our study, for the first time, provides experimental evidence that the long-term administration of mildronate not only decreases free carnitine concentration, but also causes a significant increase in GBB concentration, which correlates with the cardioprotection of mildronate." | 1.33 | Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. ( Dambrova, M; Kalvinsh, I; Kirjanova, O; Liepinsh, E; Loca, D; Pugovichs, O; Vilskersts, R, 2006) |
| "Myocardial infarction was associated with a progressive increase in length of the spared myocytes, whereas the changes in myocyte diameter were apparent only at the 1-mo interval." | 1.29 | Myocyte performance during evolution of myocardial infarction in rats: effects of propionyl-L-carnitine. ( Anversa, P; Bianchi, G; Cheng, W; Li, B; Li, P; Micheletti, R; Park, C; Sonnenblick, EH, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (20.51) | 18.7374 |
| 1990's | 23 (29.49) | 18.2507 |
| 2000's | 11 (14.10) | 29.6817 |
| 2010's | 24 (30.77) | 24.3611 |
| 2020's | 4 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Emran, T | 1 |
| Chowdhury, NI | 1 |
| Sarker, M | 1 |
| Bepari, AK | 1 |
| Hossain, M | 1 |
| Rahman, GMS | 1 |
| Reza, HM | 1 |
| Ma, D | 1 |
| Wang, L | 1 |
| Xu, C | 1 |
| Yue, L | 1 |
| Zhang, J | 1 |
| Hao, J | 1 |
| Li, HR | 1 |
| Zheng, XM | 1 |
| Liu, Y | 1 |
| Tian, JH | 1 |
| Kou, JJ | 1 |
| Shi, JZ | 1 |
| Pang, XB | 1 |
| Xie, XM | 1 |
| Yan, Y | 1 |
| Khan, A | 1 |
| Choi, Y | 1 |
| Back, JH | 1 |
| Lee, S | 1 |
| Jee, SH | 1 |
| Park, YH | 1 |
| Trainor, PJ | 1 |
| Hill, BG | 1 |
| Carlisle, SM | 1 |
| Rouchka, EC | 1 |
| Rai, SN | 1 |
| Bhatnagar, A | 1 |
| DeFilippis, AP | 1 |
| Haissman, JM | 1 |
| Haugaard, AK | 1 |
| Ostrowski, SR | 1 |
| Berge, RK | 3 |
| Hov, JR | 1 |
| Trøseid, M | 2 |
| Nielsen, SD | 1 |
| Floegel, A | 1 |
| Kühn, T | 1 |
| Sookthai, D | 1 |
| Johnson, T | 1 |
| Prehn, C | 1 |
| Rolle-Kampczyk, U | 1 |
| Otto, W | 1 |
| Weikert, C | 1 |
| Illig, T | 1 |
| von Bergen, M | 1 |
| Adamski, J | 1 |
| Boeing, H | 1 |
| Kaaks, R | 1 |
| Pischon, T | 1 |
| Liepinsh, E | 7 |
| Dambrova, M | 7 |
| Rebnord, EW | 1 |
| Strand, E | 2 |
| Pedersen, ER | 2 |
| Zhong, Z | 1 |
| Liu, J | 1 |
| Zhang, Q | 1 |
| Zhong, W | 1 |
| Li, B | 2 |
| Li, C | 1 |
| Liu, Z | 1 |
| Yang, M | 1 |
| Zhao, P | 1 |
| Sinha, A | 1 |
| Ma, Y | 1 |
| Scherzer, R | 1 |
| Rahalkar, S | 1 |
| Neilan, BD | 1 |
| Crane, H | 1 |
| Drozd, D | 1 |
| Martin, J | 1 |
| Deeks, SG | 1 |
| Hunt, P | 1 |
| Hsue, PY | 1 |
| Sizova, ZM | 1 |
| Shikh, EV | 1 |
| Makhova, AA | 1 |
| Skapare, E | 1 |
| Kuka, J | 5 |
| Makrecka, M | 3 |
| Cirule, H | 5 |
| Vavers, E | 1 |
| Sevostjanovs, E | 3 |
| Grinberga, S | 4 |
| Pugovics, O | 4 |
| Khan, HA | 1 |
| Alhomida, AS | 1 |
| DiNicolantonio, JJ | 3 |
| Lavie, CJ | 3 |
| Fares, H | 1 |
| Menezes, AR | 1 |
| O'Keefe, JH | 3 |
| Thompson, WG | 1 |
| Hensrud, DD | 1 |
| Murad, MH | 1 |
| Rizza, S | 1 |
| Copetti, M | 1 |
| Rossi, C | 1 |
| Cianfarani, MA | 1 |
| Zucchelli, M | 1 |
| Luzi, A | 1 |
| Pecchioli, C | 1 |
| Porzio, O | 1 |
| Di Cola, G | 1 |
| Urbani, A | 1 |
| Pellegrini, F | 1 |
| Federici, M | 1 |
| Niazi, AK | 1 |
| McCarty, MF | 2 |
| Liberopoulos, E | 1 |
| Makarova, E | 2 |
| Vilskersts, R | 4 |
| Lola, D | 2 |
| Loza, E | 2 |
| Stonans, I | 1 |
| Makrecka-Kuka, M | 2 |
| Kalvins, I | 1 |
| Novikov, DV | 1 |
| Belousov, SS | 1 |
| Karaulov, AV | 1 |
| Eroshevskaya, NV | 1 |
| Shumilova, SV | 1 |
| Kasatova, ES | 1 |
| Kazatskaya, ZhA | 1 |
| Novikov, VV | 1 |
| Skagen, K | 1 |
| Ueland, T | 1 |
| Holm, S | 1 |
| Abbas, A | 1 |
| Gregersen, I | 1 |
| Kummen, M | 1 |
| Bjerkeli, V | 1 |
| Reier-Nilsen, F | 1 |
| Russell, D | 1 |
| Svardal, A | 2 |
| Karlsen, TH | 1 |
| Aukrust, P | 1 |
| Hov, JE | 1 |
| Halvorsen, B | 1 |
| Skjelland, M | 1 |
| Svingen, GF | 1 |
| Olsen, T | 1 |
| Bjørndal, B | 1 |
| Karlsson, T | 1 |
| Dierkes, J | 1 |
| Njølstad, PR | 1 |
| Mellgren, G | 1 |
| Tell, GS | 1 |
| Nygård, O | 1 |
| Moselhy, SS | 1 |
| Demerdash, SH | 1 |
| Gaby, AR | 1 |
| Kalvinsh, I | 2 |
| Shah, AA | 1 |
| Craig, DM | 1 |
| Sebek, JK | 1 |
| Haynes, C | 1 |
| Stevens, RC | 1 |
| Muehlbauer, MJ | 1 |
| Granger, CB | 1 |
| Hauser, ER | 1 |
| Newby, LK | 1 |
| Newgard, CB | 1 |
| Kraus, WE | 1 |
| Hughes, GC | 1 |
| Shah, SH | 1 |
| Buziashvili, IuI | 1 |
| Kliuchnikov, IV | 1 |
| Melkonian, AM | 1 |
| Inozemtseva, EV | 1 |
| Kovalenko, OA | 1 |
| Mamaev, KhK | 1 |
| Onnis, E | 1 |
| Iliceto, S | 8 |
| Koh, SG | 1 |
| Brenner, DA | 1 |
| Korzick, DH | 1 |
| Tickerhoof, MM | 1 |
| Apstein, CS | 1 |
| Saupe, KW | 1 |
| Sethi, R | 2 |
| Wang, X | 1 |
| Ferrari, R | 2 |
| Dhalla, NS | 2 |
| Tarantini, G | 1 |
| Scrutinio, D | 3 |
| Bruzzi, P | 2 |
| Boni, L | 3 |
| Rizzon, P | 7 |
| Loca, D | 1 |
| Kirjanova, O | 1 |
| Pugovichs, O | 1 |
| Xue, YZ | 1 |
| Wang, LX | 1 |
| Liu, HZ | 1 |
| Qi, XW | 1 |
| Wang, XH | 1 |
| Ren, HZ | 1 |
| Briet, F | 1 |
| Keith, M | 1 |
| Leong-Poi, H | 1 |
| Kadakia, A | 1 |
| Aba-Alkhail, K | 1 |
| Giliberto, JP | 1 |
| Stewart, D | 1 |
| Errett, L | 1 |
| David Mazer, C | 1 |
| Spagnoli, LG | 1 |
| Corsi, M | 2 |
| Villaschi, S | 1 |
| Palmieri, G | 1 |
| Maccari, F | 1 |
| Corr, PB | 1 |
| Lee, BI | 1 |
| Sobel, BE | 1 |
| D'Annunzio, E | 4 |
| Mobilij, A | 4 |
| D'Orazio, G | 4 |
| Volpi, G | 4 |
| Olivieri, N | 1 |
| Genovesi, A | 2 |
| Del Gatto, L | 2 |
| Pavone, P | 2 |
| Sclocco, T | 4 |
| Pontono, O | 1 |
| Rasetti, G | 3 |
| Serci, T | 1 |
| Suzuki, Y | 1 |
| Kamikawa, T | 1 |
| Yamazaki, N | 1 |
| Giordano, MP | 1 |
| Roncarolo, PL | 1 |
| Gabasio, CA | 1 |
| Trevisani, C | 1 |
| Paloscia, L | 2 |
| Pontano, O | 2 |
| D'Ambrosio, G | 2 |
| Di Biase, M | 3 |
| Biasco, G | 3 |
| Hugenholtz, PG | 1 |
| Li, P | 1 |
| Park, C | 1 |
| Micheletti, R | 2 |
| Cheng, W | 1 |
| Sonnenblick, EH | 1 |
| Anversa, P | 2 |
| Bianchi, G | 2 |
| Marangelli, V | 1 |
| Corbucci, GG | 1 |
| Loche, F | 1 |
| Di Paola, ED | 1 |
| Schiavone, A | 1 |
| English, E | 1 |
| Benatti, P | 1 |
| Capasso, JM | 1 |
| Singh, RB | 1 |
| Niaz, MA | 1 |
| Agarwal, P | 1 |
| Beegum, R | 1 |
| Rastogi, SS | 1 |
| Sachan, DS | 1 |
| Arsenian, MA | 1 |
| New, PS | 1 |
| Cafasso, CM | 1 |
| Simonenko, VB | 1 |
| Teslia, AN | 1 |
| Dhalla, KS | 1 |
| Ganguly, PK | 1 |
| Colonna, P | 1 |
| Katircioglu, SF | 1 |
| Işcan, HZ | 1 |
| Ulus, T | 1 |
| Saritaş, Z | 1 |
| Yonekura, K | 1 |
| Eto, Y | 1 |
| Yokoyama, I | 1 |
| Matsumoto, A | 1 |
| Sugiura, S | 1 |
| Momomura, S | 1 |
| Kirimoto, T | 1 |
| Hayashi, Y | 1 |
| Omata, M | 1 |
| Aoyagi, T | 1 |
| Chen, SH | 1 |
| Lincoln, SD | 1 |
| Davini, P | 1 |
| Bigalli, A | 1 |
| Lamanna, F | 1 |
| Boem, A | 1 |
| Martina, B | 1 |
| Zuber, M | 1 |
| Weiss, P | 1 |
| Burkart, F | 1 |
| Ritz, R | 1 |
| Pepine, CJ | 1 |
| Leasure, JE | 1 |
| Kordenat, K | 1 |
| De Pasquale, B | 1 |
| Righetti, G | 1 |
| Menotti, A | 1 |
| Tishkin, VS | 1 |
| Dunaev, VV | 1 |
| Kryzhanovskiĭ, SA | 1 |
| Riabinin, VA | 1 |
| Favoritov, VN | 1 |
| Danilovich, MI | 1 |
| Kacharava, VG | 1 |
| Ura, K | 1 |
| Hironaka, Y | 1 |
| Sakurai, I | 1 |
| Fujisawa, S | 1 |
| Tachikawa, N | 1 |
| Murakami, E | 1 |
| Masuda, M | 1 |
| Mizutani, S | 1 |
| Mizutani, M | 1 |
| Hirose, Y | 1 |
| Yamada, H | 1 |
| Fujita, K | 1 |
| Hasebe, T | 1 |
| Lachica, E | 2 |
| Luna, A | 2 |
| Villanueva, E | 2 |
| Boscia, F | 1 |
| Rizzo, U | 1 |
| Minafra, F | 1 |
| Bortone, A | 1 |
| Siliprandi, N | 1 |
| Procopio, A | 1 |
| Bagiella, E | 1 |
| Nadeau, A | 1 |
| Tancrède, G | 1 |
| Rousseau-Migneron, S | 1 |
| Mathew, S | 1 |
| Menon, PV | 1 |
| Kurup, PA | 1 |
| DiMauro, S | 1 |
| Scott, C | 1 |
| Penn, AS | 1 |
| Rowland, LP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography[NCT00354081] | Phase 3 | 3,096 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for carnitine and Myocardial Infarction
| Article | Year |
|---|---|
Significance of L-carnitine in internal medicine.
Topics: Antioxidants; Carnitine; Cytochrome P-450 CYP3A; Heart; Heart Diseases; Heart Failure; Humans; Inter | 2019 |
L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Carnitine; Heart Failure; Humans; Myocardial Infarction; Odds | 2013 |
L-carnitine for the treatment of acute myocardial infarction.
Topics: Acyl Coenzyme A; Animals; Cardiovascular Agents; Carnitine; Energy Metabolism; Glucose; Humans; Myoc | 2014 |
Nutritional treatments for acute myocardial infarction.
Topics: Antioxidants; Ascorbic Acid; Carnitine; Dietary Supplements; Humans; Magnesium; Myocardial Infarctio | 2010 |
[Ischemic remodeling of the left ventricle (definition, pathogenesis, diagnosis, medical and surgical correction)].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2002 |
[An old strategy which comes up again: metabolic therapy of acute myocardial infarction].
Topics: Carnitine; Glucose; Humans; Insulin; Muscle Cells; Myocardial Infarction; Myocardial Ischemia; Potas | 1999 |
[Consensus conference on the therapeutic effects of L-carnitine in patients with myocardial ischemia and left ventricular remodeling].
Topics: Carnitine; Coronary Disease; Humans; Myocardial Infarction; Myocardial Ischemia; Ventricular Functio | 1998 |
Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico.
Topics: Cardiomyopathy, Dilated; Carnitine; Heart Failure; Humans; Myocardial Contraction; Myocardial Infarc | 2000 |
New thoughts of pathophysiology and therapy of ischemic heart disease.
Topics: Animals; Carnitine; Heart; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Myocar | 1991 |
[The role of metabolic therapy in myocardial infarct].
Topics: Adenosine Triphosphate; Animals; Carnitine; Heart; Humans; Lipid Metabolism; Myocardial Infarction; | 1991 |
10 trials available for carnitine and Myocardial Infarction
| Article | Year |
|---|---|
Levocarnitine normalizes elevated blood level of soluble Fas mRNA in patients with acute myocardial infarction.
Topics: Carnitine; Fas Ligand Protein; fas Receptor; Humans; Myocardial Infarction; Real-Time Polymerase Cha | 2015 |
Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial.
Topics: Carnitine; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Inf | 2006 |
L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Carnitine; Creatine Kinase, MB Form; Electrocardiograph | 2007 |
Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial.
Topics: Adult; Aged; Analysis of Variance; Carnitine; Double-Blind Method; Drug Administration Schedule; Ech | 1995 |
[Prevention of post-infarction remodelling with L-carnitine: multicenter study CEDIM (L-Carnitine digital echocardiography myocardial infarction)].
Topics: Carnitine; Double-Blind Method; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Myocardial | 1994 |
A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction.
Topics: Administration, Oral; Carnitine; Double-Blind Method; Female; Humans; Lipid Peroxides; Male; Middle | 1996 |
Controlled study on L-carnitine therapeutic efficacy in post-infarction.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carnitine; Fe | 1992 |
[Anti-arrhythmia treatment using L-carnitine in acute myocardial infarct].
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Carnitine; Double-Blind Method; Female; | 1992 |
[L-carnitine for the treatment of acute myocardial infarct].
Topics: Adult; Aged; Aged, 80 and over; Carnitine; Female; Humans; Male; Middle Aged; Multivariate Analysis; | 1990 |
High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects.
Topics: Aged; Anti-Arrhythmia Agents; Carnitine; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1989 |
58 other studies available for carnitine and Myocardial Infarction
| Article | Year |
|---|---|
L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Disease Models, Animal; Fibrosis; Inflam | 2021 |
Effect of L-carnitine on left ventricular remodeling and cardiac function after PCI in patients with acute myocardial infarction.
Topics: Carnitine; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Ventricular Function, | 2022 |
L-Carnitine Alleviates the Myocardial Infarction and Left Ventricular Remodeling through Bax/Bcl-2 Signal Pathway.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carnitine; Disease Models, Animal; Mice; Mice, Inbre | 2022 |
High-resolution metabolomics study revealing l-homocysteine sulfinic acid, cysteic acid, and carnitine as novel biomarkers for high acute myocardial infarction risk.
Topics: Aged; Amino Acids; Biomarkers; Carnitine; Cohort Studies; Cysteic Acid; Female; Homocysteine; Humans | 2020 |
Systems characterization of differential plasma metabolome perturbations following thrombotic and non-thrombotic myocardial infarction.
Topics: Adult; Aged; Blood; Carnitine; Coronary Thrombosis; Female; Gas Chromatography-Mass Spectrometry; Gl | 2017 |
Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection.
Topics: Adult; Betaine; Biomarkers; Blood Platelets; Cardiovascular Diseases; Carnitine; Choline; Cross-Sect | 2017 |
Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohorts.
Topics: Aged; Amino Acids; Biomarkers; Brain Ischemia; Carnitine; Female; Germany; Humans; Incidence; Male; | 2018 |
Letter to the Editor: "Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris".
Topics: Angina, Stable; Carnitine; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Risk Factors | 2018 |
Response to Letter to the Editor: "Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris".
Topics: Angina, Stable; Carnitine; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Risk Factors | 2018 |
Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China.
Topics: Aged; Angina, Stable; Angina, Unstable; Biomarkers; Carnitine; China; Choline; Chromatography, Liqui | 2019 |
Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Betaine; Carnitine; Carotid Artery Di | 2019 |
Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia-reperfusion.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Fatty Acids; Gene Expression Regulation; Male; | 2013 |
Single nucleotide polymorphism in CPT1B and CPT2 genes and its association with blood carnitine levels in acute myocardial infarction patients.
Topics: Adult; Aged; Aged, 80 and over; Carnitine; Carnitine O-Palmitoyltransferase; Case-Control Studies; D | 2013 |
Regarding L-carnitine and cardiovascular disease.
Topics: Carnitine; Humans; Myocardial Infarction; Secondary Prevention; Vitamin B Complex | 2013 |
In reply-regarding L-carnitine and cardiovascular disease.
Topics: Carnitine; Humans; Myocardial Infarction; Secondary Prevention; Vitamin B Complex | 2013 |
Metabolomics signature improves the prediction of cardiovascular events in elderly subjects.
Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Cardiovascular Diseases; Carnitine; Cellular Senescence; | 2014 |
Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size.
Topics: Animals; Cardiotonic Agents; Carnitine; gamma-Butyrobetaine Dioxygenase; Male; Myocardial Infarction | 2014 |
Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction.
Topics: Animals; Biological Transport; Carnitine; Dose-Response Relationship, Drug; Fatty Acids; gamma-Amino | 2015 |
The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis.
Topics: Aged; Betaine; Biomarkers; Carnitine; Carotid Stenosis; Case-Control Studies; Cause of Death; Chroma | 2016 |
Serum Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in Patients With Stable Angina Pectoris.
Topics: Aged; Angina Pectoris; Biomarkers; Carnitine; Cause of Death; Follow-Up Studies; Heart Arrest; Human | 2017 |
Decrease in Long-Chain Acylcarnitine Tissue Content Determines the Duration of and Correlates with the Cardioprotective Effect of Methyl-GBB.
Topics: Animals; Betaine; Biotransformation; Cardiotonic Agents; Carnitine; Down-Regulation; gamma-Aminobuty | 2017 |
Serum free L-carnitine in association with myoglobin as a diagnostic marker of acute myocardial infarction.
Topics: Adult; Carnitine; Creatine Kinase; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myoglob | 2009 |
The cardioprotective effect of mildronate is diminished after co-treatment with L-carnitine.
Topics: Animals; Betaine; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Chromatography | 2012 |
Metabolic profiles predict adverse events after coronary artery bypass grafting.
Topics: Aged; Biomarkers; Carnitine; Coronary Artery Bypass; Coronary Artery Disease; Energy Metabolism; Fem | 2012 |
Exercise intolerance during post-MI heart failure in rats: prevention with supplemental dietary propionyl-L-carnitine.
Topics: Animals; Carnitine; Diet; Disease Models, Animal; Exercise Tolerance; Heart Failure; In Vitro Techni | 2003 |
Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agent | 2004 |
Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction.
Topics: Animals; Betaine; Cardiovascular Agents; Carnitine; Chromatography, High Pressure Liquid; Coronary C | 2006 |
Triple nutrient supplementation improves survival, infarct size and cardiac function following myocardial infarction in rats.
Topics: Acyl-CoA Dehydrogenase; Animals; Cardiac Output; Carnitine; Carnitine O-Palmitoyltransferase; Dietar | 2008 |
Myocardial carnitine deficiency in acute myocardial infarction.
Topics: Carnitine; Humans; Myocardial Infarction; Myocardium | 1982 |
Management of acute myocardial infarction with natural physiological agents.
Topics: Acute Disease; Adenosine; Animals; Carnitine; Collateral Circulation; Dipyridamole; Dogs; Epoprosten | 1983 |
Electrophysiological and biochemical derangements in ischemic myocardium: interactions involving the cell membrane.
Topics: Animals; Arrhythmias, Cardiac; Carnitine; Cats; Cell Membrane; Coronary Disease; Electrophysiology; | 1981 |
[Clinical evaluation of the therapeutic effect of D-L-carnitine in the acute phase of myocardial infarct in relation to the behavior of the serum myoglobin concentration curve].
Topics: Aged; Aspartate Aminotransferases; Carnitine; Creatine Kinase; Humans; Middle Aged; Myocardial Infar | 1982 |
[Evaluation of the therapeutic effect of D-L-carnitine in the acute phase of myocardial infarct in reference to the behavior of the serum myoglobin concentration curve].
Topics: Aged; Carnitine; Drug Evaluation; Humans; Middle Aged; Myocardial Infarction; Myoglobin | 1982 |
Effects of L-carnitine on ventricular arrhythmias in dogs with acute myocardial ischemia and a supplement of excess free fatty acids.
Topics: Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Carnitine; Dogs; Fatty Acids, Nonesterified; | 1981 |
[Acetyl carnitine in the prevention of arrhythmic complications in acute myocardial infarct. Preliminary results].
Topics: Acetylcarnitine; Acute Disease; Arrhythmias, Cardiac; Carnitine; Humans; Myocardial Infarction | 1981 |
[Evaluation of the therapeutic action of D-L carnitine in acute myocardial infarct (AMI) by changes in the serum myoglobin concentration curve. I. Myoglobin: earliest serum test of necrosis in the acute phase of myocardial infarction].
Topics: Acute Disease; Aged; Carnitine; Humans; Middle Aged; Myocardial Infarction; Myoglobin | 1981 |
[Evaluation of the therapeutic action of D-L carnitine in acute myocardial infarct (AMI) by changes in the serum myoglobin concentration curve. II. Concluding remarks].
Topics: Acute Disease; Carnitine; Myocardial Infarction; Myoglobin | 1981 |
Myocyte performance during evolution of myocardial infarction in rats: effects of propionyl-L-carnitine.
Topics: Animals; Calcium; Cardiotonic Agents; Carnitine; Cytosol; Electric Stimulation; Heart; Male; Myocard | 1995 |
[The Italian contribution to the application of high-technology methods to clinical trials].
Topics: Cardiology; Carnitine; Clinical Trials as Topic; Computer Communication Networks; Echocardiography; | 1993 |
L-carnitine in cardiogenic shock therapy: pharmacodynamic aspects and clinical data.
Topics: Blood Gas Analysis; Carnitine; Hemodynamics; Hospitalization; Humans; Infusions, Intravenous; Myocar | 1993 |
Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats.
Topics: Administration, Oral; Animals; Blood Pressure; Carnitine; Enalapril; Hypertrophy, Left Ventricular; | 1993 |
Safety, tolerability, and efficacy of a glucose-insulin-potassium-magnesium-carnitine solution in acute myocardial infarction.
Topics: Aged; Blood Glucose; Calcium; Cardiovascular Agents; Carnitine; Diuretics; Drug Tolerance; Female; F | 1996 |
[L-carnitine in the treatment of left ventricular dysfunction in post-infarction].
Topics: Animals; Carnitine; Humans; Myocardial Infarction; Myocardial Ischemia; Ventricular Dysfunction, Lef | 1995 |
[Therapeutic action of L-carnitine in myocardial ischemia and left ventricular remodeling: clinical data].
Topics: Carnitine; Echocardiography; Humans; Hypertrophy, Left Ventricular; Myocardial Infarction; Myocardia | 1998 |
[Carnitine and solcoseryl in combined treatment of elderly and senile patients with myocardial infarction].
Topics: Actihaemyl; Aged; Carnitine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1998 |
Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction.
Topics: Adenylyl Cyclases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium; Carnitine; Heart Failu | 1999 |
Myocardial preservation in acute coronary artery occlusion with coronary sinus retroperfusion and carnitine.
Topics: Animals; Carnitine; Dogs; Energy Metabolism; Hemodynamics; Myocardial Infarction; Myocardial Reperfu | 2000 |
Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction.
Topics: Animals; Calcium-Transporting ATPases; Cardiovascular Agents; Carnitine; Hexokinase; Isoenzymes; Mal | 2000 |
Increased serum carnitine concentration in renal insufficiency.
Topics: Adult; Blood Urea Nitrogen; Carnitine; Coronary Disease; Humans; Kidney Diseases; Liver Cirrhosis; M | 1977 |
Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs.
Topics: Animals; Calcium Channel Blockers; Carnitine; Creatine Kinase; Dogs; Drug Evaluation, Preclinical; F | 1991 |
[Study of anti-ischemic action of carnitine chloride and its effects on the effectiveness of antianginal agents].
Topics: Animals; Carnitine; Cats; Clinical Enzyme Tests; Drug Therapy, Combination; Myocardial Infarction; M | 1990 |
Effect of carnitine on size limitation of experimental myocardial infarct.
Topics: Animals; Carnitine; Creatine Kinase; Dogs; Electrocardiography; Fatty Acids, Nonesterified; Female; | 1990 |
[Limitation of experimental infarct size by levo-carnitine chloride (LC-80), a new mitochondrial function-reactivating agent].
Topics: Animals; Carnitine; Disease Models, Animal; Dogs; Hemodynamics; Male; Microscopy, Electron; Mitochon | 1990 |
Usefulness of different myocardial sampling zones for the postmortem diagnosis of myocardial infarction.
Topics: Carnitine; Death, Sudden; Diagnosis, Differential; Fatty Acids, Nonesterified; Heart Septum; Heart V | 1989 |
Regional study of free fatty acids and free carnitine behavior in cardiac tissue in relation to different causes of death.
Topics: Carnitine; Cause of Death; Fatty Acids, Nonesterified; Forensic Medicine; Humans; Multiple Trauma; M | 1988 |
Acute diabetes mellitus does not impair survival rate in rats submitted to left coronary artery ligation.
Topics: Acute Disease; Animals; Blood Glucose; Carnitine; Coronary Disease; Coronary Vessels; Creatine Kinas | 1987 |
Effect of administration of carnitine on the severity of myocardial infarction induced by isoproterenol in rats.
Topics: Animals; Aspartate Aminotransferases; Carnitine; Cholesterol; Creatine Kinase; Fatty Acids; Female; | 1986 |
Serum carnitine. An index of muscle destruction in man.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carbon Isotopes; Carnitine; Ch | 1973 |